# PASS of Paediatric Patients Initiating Selumetinib

> **NCT05388370** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 124 (actual)

## Conditions studied

- Neurofibromatosis Type 1

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05388370
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-23
- **Primary completion:** 2028-05-23
- **Final completion:** 2028-05-23
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388370, "PASS of Paediatric Patients Initiating Selumetinib". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05388370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*